fda warning letters compounded semaglutide october 2025 Drug Recalls and Warnings: Recalls for and Tirzepatide, Wegovy; Facility US FDA sends 25 letters

Review the full current Terms of Service before committing

And every new trial has only reinforced my knowing it is THE gold standard for GLP-1 peptides

Results from Eli Lilly's Phase 2 trial (Jastreboff et al., New England Journal of Medicine, 2023) reported mean body weight reductions of approximately 1724% over 48 weeks depending on dose, which has generated considerable scientific interest

August 12 Product: Ascendis Pharmas Yorvipath Indication: Hypoparathyroidism After a long regulatory road, Ascendis Pharma received FDA approval Monday for Yorvipath (TransCon PTH) for the treatment of hypoparathyroidism, a rare endocrine disease characterized by abnormally low levels of the parathyroid hormone

GLP-1 medications are prescription-only, and they're not for everyone